Booster Study of COVID-19 Protein Subunit Recombinant Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Observer-blind, randomized, active-controlled prospective intervention study of Immunogenicity \& Safety of SARS-Cov-2 Protein Subunit Recombinant Vaccine (Bio Farma) as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older.
Epistemonikos ID: 16a926e93c94d93a10266bb37a6847c49c46a776
First added on: Sep 02, 2022